MedTrace Logo

Prescription of Benzodiazepines by General Practitioners: Characteristics of Prescribing Trend and Implementation of an Online Educational Program

NCT04925596 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-06-14

No results posted yet for this study

Summary

Portugal has the highest benzodiazepine utilization compared to other European countries. The high utilization of benzodiazepines has been a concern due to reported side effects of long-term use and dependence. Also, these data demonstrate that doctors are possibly choosing an inadequate treatment to manage anxious and depressive syndromes.

This research aims to develop and implement in primary health care units an online educational program, following a cluster randomized study design; to study the impact of this educational program for changing general practitioner's benzodiazepine prescription pattern; to analyze of barriers and facilitators to the implementation of the e-PrimaPrescribe program.

Conditions

  • Anxiety
  • Prescription Drug Abuse and Dependency

Interventions

BEHAVIORAL

ePrimaPrescribe online educational program

online training program aiming to change general practitioners' benzodiazepine prescription

BEHAVIORAL

ComunicaSaudeMental online educational program

online training program aiming to improve general practitioners' communication with mentally ill patients

Sponsors & Collaborators

  • Universidade Nova de Lisboa

    lead OTHER

Principal Investigators

  • Teresa Reis, Md · Universidade Nova de Lisboa

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-05-15
Completion
2019-04-09

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04925596 on ClinicalTrials.gov